专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008069890A2 ADRENAL GRK2 ACTIVITY AS A THERAPEUTIC TARGET FOR HEART FAILURE 审中-公开
标题翻译： ADRENAL GRK2活动作为心脏失效的治疗目标
公开(公告)号：WO2008069890A2
公开(公告)日：2008-06-12
申请号：PCT/US2007/023628
申请日：2007-11-09
申请人： THOMAS JEFFERSON UNIVERSITY , LYMPEROPOULOS, Anastasios , KOCH, Walter, J.
发明人： LYMPEROPOULOS, Anastasios , KOCH, Walter, J.
IPC分类号： A61K48/00
CPC分类号： A61K48/0075 , A61K48/0058 , C12N9/1205
摘要： The present invention relates to compositions and methods for the treatment of failing hearts. More specifically, the present invention provides for the inhibition of G-protein coupled receptor kinase 2 activity in the adrenal gland, which, for example, decreases catecholamine secretion and the sympathetic burden of the failing heart, thereby improving the cardiac adrenergic/inotropic reserve and overall contractile function.
摘要翻译：本发明涉及治疗失败的心脏的组合物和方法。更具体地，本发明提供抑制肾上腺中的G蛋白偶联受体激酶2活性，其例如降低儿茶酚胺分泌和失败心脏的交感负担，从而改善心脏肾上腺素能/肌力储备和整体收缩功能。

2. 发明申请

WO2008054713A2 TISSUE SPECIFIC GENE THERAPY TREATMENT 审中-公开
标题翻译：组织特异性基因治疗
公开(公告)号：WO2008054713A2
公开(公告)日：2008-05-08
申请号：PCT/US2007022861
申请日：2007-10-30
申请人： UNIV JEFFERSON , KOCH WALTER J , PLEGER SVEN T , MOST PATRICK , RABINOWITZ JOSEPH E
发明人： KOCH WALTER J , PLEGER SVEN T , MOST PATRICK , RABINOWITZ JOSEPH E
IPC分类号： C12N15/09
CPC分类号： C12N15/86 , C07K14/4728 , C12N2750/14143 , C12N2830/008
摘要： The invention provides nucleic acid segments, compositions and methods for the treatment of heart failure, vascular dysfunction, endothelial dysfunction, diabetes, [Ca 2+ ]i regulation and NO synthase dysfunction. Adeno-associated and adenovirus are used as gene delivery vectors for the nucleic acid segments to product long term over-expression of S100A1, a small calcium sensing protein associated with the disclosed ailments and dysfunctions.
摘要翻译：本发明提供了用于治疗心力衰竭，血管功能障碍，内皮功能障碍，糖尿病，[Ca 2+]调节和NO合成酶功能障碍的核酸区段，组合物和方法。腺相关腺病毒和腺病毒用作核酸片段的基因递送载体，以产生S100A1的长期过表达，S100A1是与所公开的疾病和功能障碍相关的小的钙感觉蛋白。

3. 发明申请

WO2006052857A3 BIOMARKER FOR HEART FAILURE 审中-公开
标题翻译：生物标志物用于心力衰竭
公开(公告)号：WO2006052857A3
公开(公告)日：2006-10-19
申请号：PCT/US2005040231
申请日：2005-11-04
申请人： UNIV DUKE , KOCH WALTER J , IACCARINO GUIDO
发明人： KOCH WALTER J , IACCARINO GUIDO
IPC分类号： G01N33/53 , G01N33/543
CPC分类号： C12Q1/6883 , C12Q1/485 , C12Q2600/158 , G01N33/5091 , G01N33/573
摘要： The present invention relates, in general, to heart failure, and, in particular, to a method of evaluating heart failure patients by monitoring ß-adrenergic receptor kinase (ßARK1) levels in lymphocytes from such patients.
摘要翻译：本发明一般涉及心力衰竭，并且特别涉及通过监测来自这些患者的淋巴细胞中的β-肾上腺素能受体激酶（βARK1）水平来评估心力衰竭患者的方法。

4. 发明申请

WO2006052857A2 BIOMARKER FOR HEART FAILURE 审中-公开
标题翻译：生物标记为心脏失败
公开(公告)号：WO2006052857A2
公开(公告)日：2006-05-18
申请号：PCT/US2005/040231
申请日：2005-11-04
申请人： DUKE UNIVERSITY , KOCH, Walter, J. , IACCARINO, Guido
发明人： KOCH, Walter, J. , IACCARINO, Guido
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q1/485 , C12Q2600/158 , G01N33/5091 , G01N33/573
摘要： The present invention relates, in general, to heart failure, and, in particular, to a method of evaluating heart failure patients by monitoring β-adrenergic receptor kinase (βARK1) levels in lymphocytes from such patients.
摘要翻译：本发明一般涉及心力衰竭，特别涉及通过监测来自这些患者的淋巴细胞中的β-肾上腺素能受体激酶（ßARK1）水平来评价心力衰竭患者的方法。

5. 发明申请

WO2012048022A3 METHODS AND COMPOSITIONS FOR THERAPEUTIC MODULATION OF ALDOSTERONE LEVELS IN HEART DISEASE 审中-公开
标题翻译：心脏疾病中阿尔托斯酮水平的治疗方法和组合物
公开(公告)号：WO2012048022A3
公开(公告)日：2012-06-21
申请号：PCT/US2011054955
申请日：2011-10-05
申请人： UNIV NOVA SOUTHEASTERN , UNIV JEFFERSON , LYMPEROPOULOS ANASTASIOS , KOCH WALTER J
发明人： LYMPEROPOULOS ANASTASIOS , KOCH WALTER J
IPC分类号： A61K38/00 , A61K38/04 , A61K38/22 , A61K38/55 , C07K1/00
CPC分类号： A61K38/085 , A61K31/41 , A61K31/4184 , A61K38/1709 , A61K2300/00
摘要： The disclosure describes the contribution of elevated levels of circulating alsosterone to heart disease and other hyperaldosteronic conditions. Since activation of beta-arrestin I (beta.arr-1) by the Angiotensin II (Angll) type 1 receptor (AT1R) mediates Angll-induced aldosterone production, beta-arrestin I (beta.arr-1) is a therapeutic target for heart disease. Specifically, the disclosure provides a beta.arr-1 protein fragment comprising the C-terminus of beta.arr-1 (beta.arrlct; SEQ ID NO:3), compositions containing this protein fragment, and methods of using this protein fragment to reduce elevated levels of aldosterone in heart disease and other hyperaldosteronic conditions by inhibition of beta-arrestin (beta.arr-1). These compositions and methods are of therapeutic benefit in chronic heart failure and progression to heart failure after myocardial infarction (Ml). Additionally, the invention provides an Angll peptide analog (SEQ ID NO:4), compositions containing this analog, and methods of using this analog for stimulation of beta.arr-1 activity and aldosterone production.
摘要翻译：该公开内容描述了循环性强酮水平升高对心脏病和其它醛固酮增多症状的贡献。由于血管紧张素II（AngII）1型受体（AT1R）的β-arrestin I（beta.arr-1）的激活介导AngII诱导的醛固酮生成，因此β-抑制蛋白I（betaarr-1）是治疗靶点心脏病。具体地，本公开提供了包含beta.arr-1（beta.arrlct; SEQ ID NO：3）的C末端的beta.arr-1蛋白质片段，含有该蛋白质片段的组合物，以及使用该蛋白质片段通过抑制β-抑制蛋白（beta.arr-1）降低心脏病和其他醛固酮增多症状中醛固酮的水平升高。这些组合物和方法在心肌梗塞后在慢性心力衰竭和心力衰竭进展中具有治疗益处（M1）。此外，本发明提供了AngII肽类似物（SEQ ID NO：4），含有该类似物的组合物，以及使用该类似物刺激beta.arr-1活性和醛固酮产生的方法。

6. 发明申请

WO2012048022A2 METHODS AND COMPOSITIONS FOR THERAPEUTIC MODULATION OF ALDOSTERONE LEVELS IN HEART DISEASE 审中-公开
标题翻译：心脏疾病中阿尔托斯酮水平的治疗方法和组合物
公开(公告)号：WO2012048022A2
公开(公告)日：2012-04-12
申请号：PCT/US2011/054955
申请日：2011-10-05
申请人： NOVA SOUTHEASTERN UNIVERSITY , THOMAS JEFFERSON UNIVERSITY , LYMPEROPOULOS, Anastasios , KOCH, Walter, J.
发明人： LYMPEROPOULOS, Anastasios , KOCH, Walter, J.
IPC分类号： A61K38/08
CPC分类号： A61K38/085 , A61K31/41 , A61K31/4184 , A61K38/1709 , A61K2300/00
摘要： The invention concerns the contribution of elevated levels of circulating alsosterone to heart disease and other hyperaldosteronic conditions. Since activation of β-arrestin 1(βarr- 1) by the Angiotensin II (Angll) type 1 receptor (AT 1 R) mediates Angll- induced aldosterone production, β-arrestin 1(βarr-1) is a therapeutic target for heart disease. The invention provides a βarr1 protein fragment comprising the C-terminus of βarr1 (βarr1ct; SEQ ID NO:3), compositions containing this protein fragment, and methods of using this protein fragment to reduce elevated levels of aldosterone in heart disease and other hyperaldosteronic conditions by inhibition of β-arrestin 1(βarr1). These compositions and methods are of therapeutic benefit in chronic heart failure and progression to heart failure after myocardial infarction (MI). Additionally, the invention provides an AngII peptide analog (SEQ ID NO:4), compositions containing this analog, and methods of using this analog for stimulation of βarr-1 activity and aldosterone production.
摘要翻译：本发明涉及循环性强酮水平升高对心脏病和其它醛固酮增多症状的贡献。由于血管紧张素II（AngII）1型受体（AT1R）的β-arrestin1（ßarr-1）的激活介导AngII诱导的醛固酮生成，β-arrestin 1（ßarr-1）是心脏病的治疗靶点。本发明提供包含ßarr1（ßarr1ct; SEQ ID NO：3）的C末端的ßarr1蛋白质片段，含有该蛋白质片段的组合物，以及使用该蛋白质片段降低心脏病和其它醛固酮增多症状中醛固酮升高的方法通过抑制β-arrestin 1（ßarr1）。这些组合物和方法在心肌梗塞（MI）后在慢性心力衰竭和进展为心力衰竭中具有治疗益处。另外，本发明提供AngII肽类似物（SEQ ID NO：4），含有该类似物的组合物，以及使用该类似物刺激ßarr-1活性和醛固酮生产的方法。

7. 发明申请

WO2008069890A3 ADRENAL GRK2 ACTIVITY AS A THERAPEUTIC TARGET FOR HEART FAILURE 审中-公开
标题翻译： ADRENAL GRK2活性作为治疗心力衰竭的目标
公开(公告)号：WO2008069890A3
公开(公告)日：2008-10-30
申请号：PCT/US2007023628
申请日：2007-11-09
申请人： UNIV JEFFERSON , LYMPEROPOULOS ANASTASIOS , KOCH WALTER J
发明人： LYMPEROPOULOS ANASTASIOS , KOCH WALTER J
IPC分类号： A61K48/00
CPC分类号： A61K48/0075 , A61K48/0058 , C12N9/1205
摘要： The present invention relates to compositions and methods for the treatment of failing hearts. More specifically, the present invention provides for the inhibition of G-protein coupled receptor kinase 2 activity in the adrenal gland, which, for example, decreases catecholamine secretion and the sympathetic burden of the failing heart, thereby improving the cardiac adrenergic/inotropic reserve and overall contractile function.
摘要翻译：本发明涉及用于治疗衰竭心脏的组合物和方法。更具体地，本发明提供了肾上腺中G蛋白偶联受体激酶2活性的抑制，其例如降低儿茶酚胺分泌和心力衰竭的交感神经负担，由此改善心脏肾上腺素能/收缩力储备，并且整体收缩功能。

8. 发明申请

WO2008054713A3 TISSUE SPECIFIC GENE THERAPY TREATMENT 审中-公开
公开(公告)号：WO2008054713A3
公开(公告)日：2008-05-08
申请号：PCT/US2007/022861
申请日：2007-10-30
申请人： THOMAS JEFFERSON UNIVERSITY , KOCH, Walter, J. , PLEGER, Sven, T. , MOST, Patrick , RABINOWITZ, Joseph, E.
发明人： KOCH, Walter, J. , PLEGER, Sven, T. , MOST, Patrick , RABINOWITZ, Joseph, E.
IPC分类号： C07K14/47 , C12N15/861
摘要： The invention provides nucleic acid segments, compositions and methods for the treatment of heart failure, vascular dysfunction, endothelial dysfunction, diabetes, [Ca 2+ ]i regulation and NO synthase dysfunction. Adeno-associated and adenovirus are used as gene delivery vectors for the nucleic acid segments to product long term over-expression of S100A1, a small calcium sensing protein associated with the disclosed ailments and dysfunctions.

9. 发明专利

IL183036D0 BIOMARKER FOR HEART FAILURE 未知
公开(公告)号：IL183036D0
公开(公告)日：2007-09-20
申请号：IL18303607
申请日：2007-05-07
申请人： UNIV DUKE , KOCH WALTER J , IACCARINO GUIDO
IPC分类号： G01N20100101
摘要： The present invention relates, in general, to heart failure, and, in particular, to a method of evaluating heart failure patients by monitoring beta-adrenergic receptor kinase (betaARK1) levels in lymphocytes from such patients.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式